No high-quality evidence supports cannabis for anxiety, depression, or insomnia in cancer patients
A MASCC systematic review of 15 randomized trials found no high-quality evidence to recommend cannabis for psychological symptoms in cancer patients, though 6 of 15 trials suggested some benefit for sleep.
Quick Facts
What This Study Found
From 829 articles screened, 2 systematic reviews and 15 RCTs met criteria. No studies assessed cannabis efficacy on psychological symptoms as primary outcomes in cancer. Studies varied widely in interventions, controls, duration, and outcomes. Six of 15 RCTs suggested benefits: five for sleep and one for mood. The evidence was insufficient to recommend cannabis for anxiety, depression, or insomnia in cancer patients.
Key Numbers
829 articles screened; 15 RCTs and 2 systematic reviews included; 4 studies on sleep, 5 on mood, 6 on both; 6/15 suggested benefits (5 for sleep, 1 for mood)
How They Did This
Systematic review searching MEDLINE, CCTR, EMBASE, and PsychINFO up to November 2021. Inclusion criteria: randomized controlled trials and systematic reviews of cannabis versus placebo or active comparator in cancer patients with psychological symptom outcomes.
Why This Research Matters
With 18% of cancer patients already using cannabis for symptom management, this guideline from a major supportive care organization provides important clarity: the evidence does not yet support this practice for psychological symptoms.
The Bigger Picture
Cancer patients using cannabis for anxiety and depression are doing so in an evidence vacuum. Until high-quality trials with psychological symptoms as primary outcomes are conducted, clinical decisions rely on extrapolation from inadequate data.
What This Study Doesn't Tell Us
No RCTs had psychological symptoms as primary outcomes, making all evidence secondary. Studies were heterogeneous in cannabis type, dose, and measurement tools. Search limited to November 2021.
Questions This Raises
- ?Would RCTs specifically designed to assess cannabis for cancer-related insomnia confirm the promising signals from secondary analyses?
- ?Why has no trial prioritized psychological outcomes despite widespread patient use?
Trust & Context
- Key Stat:
- 0 RCTs assessed psychological symptoms as primary outcomes in cancer patients using cannabis
- Evidence Grade:
- Rigorous systematic review from a major cancer supportive care organization, but limited by the poor quality and heterogeneity of available trials.
- Study Age:
- Published 2023
- Original Title:
- Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression.
- Published In:
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31(3), 176 (2023)
- Authors:
- De Feo, Giulia(2), Case, Amy A(5), Crawford, Gregory B(3), Hui, David, To, Josephine, Sbrana, Andrea, Alderman, Bryony, Mukhopadhyay, Sandip, Bouleuc, Carole, Amano, Koji, Tanco, Kimberson, Garsed, Jessica, Davis, Mellar
- Database ID:
- RTHC-04490
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with anxiety or depression in cancer patients?
Current evidence is insufficient. A systematic review of 15 randomized trials found no study specifically designed to test this, and only 1 of 15 trials suggested mood benefits. The MASCC guidelines cannot recommend cannabis for these symptoms.
Can cannabis help cancer patients sleep?
There are some promising signals. Five of 15 randomized trials suggested sleep benefits, but study designs varied widely and none had insomnia as a primary outcome.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04490APA
De Feo, Giulia; Case, Amy A; Crawford, Gregory B; Hui, David; To, Josephine; Sbrana, Andrea; Alderman, Bryony; Mukhopadhyay, Sandip; Bouleuc, Carole; Amano, Koji; Tanco, Kimberson; Garsed, Jessica; Davis, Mellar. (2023). Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31(3), 176. https://doi.org/10.1007/s00520-023-07628-3
MLA
De Feo, Giulia, et al. "Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. https://doi.org/10.1007/s00520-023-07628-3
RethinkTHC
RethinkTHC Research Database. "Multinational Association of Supportive Care in Cancer (MASC..." RTHC-04490. Retrieved from https://rethinkthc.com/research/de-2023-multinational-association-of-supportive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.